Growth inhibition of pancreatic tumor cells by modified antisense oligodeoxynucleotides

Langenbeck's Archives of Surgery

Volumn 383, Issue 3-4, 1998, Pages 269-275

  Fiedler, Alexander ^a   Knorre, Christoph ^a   Franke, Yvonne ^a   Henne Bruns, Doris ^a   Kremer, Bernd ^a   Lüttges, Jutta ^a   Maier, Martin ^b   Gerster, Michael ^b   Bleicher, Konrad ^b   Bayer, Ernst ^b   Kalthoff, Holger ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antisense oligodeoxynucleotides; Cell culture; p53; Pancreatic cancer

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEIN P53;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CELL COUNT; CELL LINE; FIBROBLASTS; HUMANS; K562 CELLS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 7344229193     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050131     Document Type: Article

References (35)

1. Warshaw AL, Fernández-del Castillo C (1992) Pancreatic carcinoma. New Engl J Med 326:455-465
2. Farrow, DC, Davis S (1990) Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 45:816-820
3. Henne-Bruns D, Vogel I, Lüttges J, Klöppel G, Kremer B (1998) Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology (in press)
4. Ishikawa O (1996) Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Hepatogastroenterology 43:320-325
5. Schutte M, Kern SE (1996) The molecular genetics of pancreatic adenocarcinoma. In: Neoptolemus JP, Lemoine NR (eds) Pancreatic cancer. Blackwell, Oxford, London, pp 115-132
6. Almoguera C, Shibata D, Forrester K (1988) Most carcinomas of the human exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554
7. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A. Lauer G, Thiele HG, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H, Deppert W (1993) p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
9. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4578
10. Harvey M, Vogel H, Morris D, Bradley A, Berstein A, Donehower LA (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice Nat Genet 9:305-311
11. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Morre M, Finlay C, Levine AJ (1993) Gain of function mutations in p53 Nat Genet 4:42-45
12. Milligan JF, Matteuci MD, Martin JC (1993) Current concepts in antisense drug design. J Med Chem 36:1923-1937
13. Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical. Science 261:1004-1012
14. Bennett CF, Chiang MY, Chan H, Shoemaker JEE, Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides Mol Pharmacol 41:1023-1033
15. Helene C, Toulme J (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99-125
16. Shaw JP, Kent K, Bird J, Fishback J, Froehler BF (1991) Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucl Acids Res 19:747-750
17. Bayever E, Haines KM, Iversen PL, Ruddon RW, Pirruccello SJ, Mountjoy CP, Arneson MA, Smith LJ (1993) Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequence. Leuk Lymphoma 12:223-231
18. Bayever E, Iversen PL, Bishop M, Sharp J, Tweary H, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G, Armitage J (1994) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute meylogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 4:43-52
19. Bayer E, Maier M, Bleicher K, Gaus H-J (1995) Synthesis of 3′-PEG modified oligonucleotides on PS-PEG tentacle polymers. Z Naturforsch, 50b:671-676
20. Bayer E, Bleicher K, Maier M (1995) Improved conditions for solid phase synthesis of oligonucleotides on PS-PEG copolymers. Z Naturforsch 50 b: 1096-1100
21. MacKellar C, Graham D, Will DW, Burgess S, Brown T (1992) Synthesis and physical properties of anti-HIV oligonucleotides bearing terminal lipophilic groups. Nucl Acids Res 20:3411-3417
22. Durand M, Chevrie K, Chassignol M, Thoung NT, Maurizot JC (1990) Circular dichroism studies of an oligodeoxyribonucleotide containing a hairpin loop made of hexaethylene glycol chain: conformation and stability. Nucl Acids Res 18:6353-6359
23. Feinstein E, Gale RP, Reed J, Canaani E (1992) Expression of the normal p53 gene induces differenciation of K562 cells. Oncogene 7:1853-1857
24. Hirota Y, Horiuchi T, Akahane K (1996) p53 Antisense oligonucleocide inhibits growth of human colon and normal cell lines. Jpn J Cancer Res 87:735-742
25. Yakubov LA, Deeva EA, Zarytova VF, Ivanova E, Ryle A, Yurchenko L, Vlassov V (1989) Mechanism of oligonucleotide uptake by cells: involvement of specific receptors. Proc Natl Acad Sci USA 86:6454-6458
26. Iversen PL, Zhu S, Meyer A, Zon G (1992) Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 2:211-222
27. Sawai Y, Kitahara N, Thung WL, Yanokura M, Tsukada K (1981) Nuclear localization of ribonuclease H and increased level of magnesium-dependent ribonuclease H in rat liver on thioacetamide treatment. J Biochem 90:11-16
28. Dash P, Lotan I, Knapp M, Kandel ER, Goelet P (1987) Selective elimination of mRNA in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci U S A 84:7896-7890
29. Giles RV, Spiller DG, Tidd DM (1995) Detection of ribonuclease H-generated fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 5:23-31
30. Giles RV, Spiller DG, Tidd DM (1993) Chimeric oligodeoxynucleotide analogues: enhanced uptake of structures which direct ribonuclease H with high specificity. Anticancer Drug Des 8:33-51
31. Barton CM, Lemoine NR (1995) Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expresssion. Br J Cancer 71:429-437
32. Herschlag D (1991) Implication of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci U S A 88:6921-6925
33. Woolf TM, Melton DA, Jennings CGB (1992) Specificity of antisense olisonucleotides in vivo. Proc Natl Acad Sci USA 89:7305-7309
34. Will DW, Brown T (1992) Attachment of vitamin E derivatives to oligonucleotides during solid-phase synthesis. Tetrahedon Lett 33:2729-2732
35. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H (1998) Human pancreatic adenocarcinomas express fas and fasligand yet are resistant to fas-mediated apoptosis. Cancer Res (in press)